Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension. 1988

J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
Department of Internal Medicine C, Diakonissestiftelsen, Frederiksberg Hospital, Denmark.

Eight patients with a diastolic blood pressure greater than or equal to 100mm Hg when treated with a diuretic and a beta-blocker participated in a randomised crossover study comparing the haemodynamic effects of adjunctive therapy with pinacidil or hydralazine. The vasodilator dose was increased until the diastolic blood pressure was less than 90mm Hg or the maximum dosage, hydralazine 100mg twice daily, or pinacidil 50mg twice daily, was reached. Treatment continued for 3 to 6 months and a haemodynamic study was performed. After washout, the patients received the alternative treatment. In the upright position, during supine rest and during isometric as well as dynamic exercise, pinacidil lowered blood pressure more effectively than hydralazine. No differences between the 2 treatments were found in heart rate, stroke index, cardiac index, end systolic wall stress or glomerular filtration rate. Pulmonary mean and wedge pressure were lower during treatment with pinacidil. Forearm blood flow was higher and forearm vascular resistance lower during treatment with pinacidil. Cardiac contractility, judged from the systolic time interval ratio PEP: LVET, was lower during treatment with pinacidil compared with hydralazine. The median daily dose of pinacidil was 50mg and that of hydralazine 200mg. It was also noted that during long term treatment, pinacidil seemed more effective in reducing blood pressure than hydralazine.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006830 Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Hydrallazin,Apresoline,Apressin,Apressoline,Hydralazine Hydrochloride,Hydralazine mono-Hydrochloride,Hydrazinophthalazine,Nepresol,Hydralazine mono Hydrochloride,Hydrochloride, Hydralazine,mono-Hydrochloride, Hydralazine

Related Publications

J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
February 1984, The Journal of the Association of Physicians of India,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
January 1986, European journal of respiratory diseases. Supplement,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
September 1986, British journal of clinical pharmacology,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
January 1973, Clinical pharmacology and therapeutics,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
January 1986, European journal of clinical pharmacology,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
April 1977, British journal of clinical pharmacology,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
February 1955, Il Progresso medico,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
January 1988, Drugs,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
October 1954, Prensa medica argentina,
J E Carlsen, and H A Jensen, and M Rehling, and J O Lund, and J Trap-Jensen
January 1985, European journal of clinical pharmacology,
Copied contents to your clipboard!